



**American University of Armenia**

**Department of Public Health**

**DETERMINATION OF ATTACK PRECIPITATING FACTORS FOR  
FAMILIAL MEDITERRANEAN FEVER**

Research grant proposal for a case-crossover study

Yelena Amirkhanyan  
MPH candidate

Yerevan, 2001

## Table of content

<i>Acknowledgments</i> .....	<i>i</i>
<i>Executive summary</i> .....	<i>ii</i>
<i>Specific aims</i> .....	<i>1</i>
<i>Background</i> .....	<i>3</i>
<i>Methods/study design</i> .....	<i>7</i>
<i>Study instrument</i> .....	<i>8</i>
<i>Study population</i> .....	<i>8</i>
<i>Sample size</i> .....	<i>9</i>
<i>Data collection</i> .....	<i>10</i>
<i>Data analysis</i> .....	<i>10</i>
<i>Study limitations</i> .....	<i>11</i>
<i>Time frame</i> .....	<i>12</i>
<i>Ethical considerations</i> .....	<i>13</i>
<i>Budget</i> .....	<i>14</i>
<i>Personnel responsibilities</i> .....	<i>14</i>
<i>References</i> .....	<i>15</i>
<i>Appendix 1</i>	
<i>Appendix 2</i>	
<i>Attachment 1</i>	
<i>Attachment 2</i>	

### *Acknowledgments*

I would like to express my deepest gratefulness to my advisor Dr. Haroutune Armenian for his continuous support, useful comments and commitment to student's interest.

I want to express my gratitude to Michael Thompson for his constructive comments and suggestions. I would like to thank Susan MacMarlin for her enthusiastic support and readiness to help.

I am grateful to all professors of MPH program that share their knowledge and experience with us.

I am also grateful to administration of the Center of Medical Genetics, namely to Tamara Sarkisyan, and especially to Ara Beglaryan for his knowledgeable recommendations and support.

I want to express my gratefulness to all CHSR staff, especially to Anahit Demirchyan for her willingness to help and continuous support.

I am also grateful to MPH students for their useful comments and support.

### *Executive summary*

**Background.** Familial Mediterranean Fever (FMF) is an inherited disorder characterized by recurrent attacks of fever, peritonitis, pleuritis, arthritis and skin lesions. The disease is restricted primarily to the populations of Mediterranean basin. The prevalence rate varies among Mediterranean populations. The estimated prevalence rate for Armenians is 1 per 400. The frequency of the affected gene is the highest for Armenians living in Armenia.

A typical attack lasts from 1 to 4 days. During the attack free period patients generally appear healthy. The only serious complication of FMF is amyloidosis, which gradually leads to the renal insufficiency. The most effective medication currently used for treatment of FMF is colchicine, which reduces the frequency of attacks.

**Research question and objectives.** The goal of the proposed research is to determine what factors determine the occurrence of FMF attacks. The objectives are:

- To define the association between occurrence of attacks and high-fat food, physical stress, emotional stress, cold, climate and menstruation.
- To determine the association between different types of genetic mutations and various attack precipitants.

**Methods.** The fact that attacks of FMF have no periodicity and regularity, leads to the idea of existence of specific extraneous or environmental attack precipitating factors. The most commonly discussed are high-fat food, emotional, excessive physical activity, cold, climate and menstruation. The proposed case-crossover study is aimed to reveal association between occurrence of attacks and possible attack precipitants.

**Study instrument** is a questionnaire comprising demographic questions and domains on the disease history, hormonal status, general lifestyle and lifestyle regarding the past two-three days period.

**Sample size.** The proposed sample size is equal to 300 cases and 300 controls. Taking into account that cases and controls are the same people, the total number of participants is 300. The sample will be selected from the database of the Center of Medical Genetics of the National Academy of Sciences of Republic of Armenia.

**Analysis.** During the analysis the chi-square test will be used for determination of association between occurrence of attack and discussed attack precipitants. It will be used also for detection of associations between different types of mutations and various attack precipitants.

It is expected that the results of the study will allow to prevent development of attacks and to minimize the treatment with Colchicine.

*Specific aims*

Familial Mediterranean Fever (FMF) is a genetic disorder starting primarily in childhood and characterized by recurrent attacks of fever, peritonitis, pleurisy, arthritis and skin lesions. During the attacks patients are not able to maintain their usual level of social activity and are often in need of caretakers. These conditions create a burden on the health care system and on the society as well. The research question of the proposed study is following: What factors determine the occurrence of FMF attacks? The objectives of this study are:

- To define the association among occurrence of FMF attacks and high-fat food, physical stress, emotional stress, cold, climate and menstruation?
- To determine the association between different types of genetic mutations and various attack precipitants.

Patients for the proposed study will be selected from the database of the Center of Medical Genetics (CMG) of the National Academy of Sciences of Republic of Armenia. The database consists of about 1,500 patients with genetically verified diagnosis of FMF. The initial permission for access to the database was obtained from the administration of the Center of Medical Genetics.

The major aim of this study is to the correlation between the development of attacks and the hypothesized precipitating factors. If the association is determined it will be promising to investigate in future correlation between various types of mutations and environmental factors, namely attack precipitants.

## ***Background***

Familial Mediterranean Fever is an inherited disorder characterized by intermittent attacks of fever with sterile peritonitis, pleurisy, or synovitis (1). The words “familial Mediterranean fever” refer to the three classic features of the disease. Another name of this disease is Familial Paroxysmal Polyserositis (FPP), which reflects the clinical and pathological features of the disease.

The disease affects mostly four populations of eastern Mediterranean descent, namely non-Ashkenazi Jews, Armenians, Turks, and Arabs. It has an autosomal recessive mode of inheritance (2). The prevalence rate of FMF varies among the Mediterranean population, being 200 per 100,000 for Non-Ashkenazi Jews, and 2.0-2.5 per 100,000 for Levant Arabs (3). Data about the prevalence rate for Armenians is controversial. According to Khachadurian and Armenian (4) it is 100 per 100,000 for Armenians in Lebanon compared to 200 per 100,000 for Armenians living in Fresno County, California. The prevalence rate reported in a News release from the US National Institute of Health is 1 per 200 (5). Thus, the prevalence rate among Armenians varies from 1 per 200 [500 per 100,000] to 1 per 1000 [100 per 100,000] (5,6). This discrepancy could be explained by lack of studies on the epidemiology of FMF. According to the literature, the frequency of the affected gene is the highest for Armenians living in Armenia. (7). The disease occurs more often among males and the sex ratio according to different studies ranges between 1.5-2 per 1 (2,4).

The onset of the disease varies among patients. It starts during the first decade of life in almost 50 % of cases, and only in 5 % of cases it manifests after the age 30 years (8). By the age 20 years about 90 % of patients have already had their first attack (3).

The manifestations of the disease also vary between patients. Usually, the first attack is diagnosed retrospectively regardless of its clinical manifestation. Many patients, especially during the first abdominal manifestation of the disease, undergo surgical treatment as acute appendicitis is suspected. Almost all patients experience abdominal pain during attacks (2,9). About 50 % of Arab, Turkish, and Jewish patients experience chest attacks, which manifests with chest pain and fever; this percentage is even higher for Armenian patients. Less than half of all patients complain about joint pain. The next common manifestation of FMF is skin lesions with the frequency ranging from 3 to 46 % among the different affected populations. Scrotal inflammation, myalgia and certain types of vasculitis are among the uncommon clinical syndromes (2).

In some cases the disease manifests as amyloidosis. It is the only severe complication of FMF that determines the fatal prognosis for FMF. Amyloidosis results from the deposition of amyloid A protein, which infiltrates the various organs. Precipitation of amyloid protein in the kidneys leads to the development of renal insufficiency progressing to the renal failure. Amyloidosis can occur in patients after experiencing typical attacks, or its development can precede typical attacks (10).

The frequency of attacks ranges from days to months. In the preceding hours, some patients experience a prodrome. Attacks are characterized by fever, inflammation, and pain, usually in the peritoneum, pleura, joints, or skin. The duration of attacks ranges from 48 to 96 hours. Arthritic attacks unlike peritoneal or pleural attacks may last for weeks (6). During attack free periods patients typically appear healthy, except for those who have protracted arthritis. Protracted synovial attacks may restrict the patients' activity and keep them away from work for long time (10).

Since the 1950s, a number of drugs were prescribed for the treatment and/or prevention of FMF attacks. Among them were various antibiotics, corticosteroids, sex hormones, vitamins, analgesics, salicylates and related compounds (11). Starting in the 1960s, colchicine was introduced for the treatment and prevention of attacks. In 1974 independent randomized placebo-controlled trials demonstrate colchicine's effectiveness (2). Currently it is the treatment of choice for FMF. The daily regimen of 1-2 milligrams of colchicine diminishes the frequency of attacks or even prevents attacks. Colchicine is also recommended for the treatment of amyloidosis. However, it is not a harmless drug because of its side effects, such as gastrointestinal disorders, myopathy and neuropathy (12). Although no prospective studies have been conducted on colchicine's influence on sperm count, there is evidence in the literature that it is undesirable to administer colchicine to young males of reproductive activity (2,13).

During the past decade investigations on the cause of the disease primarily focused on the genetic aspects of the disease. In 1997 the MEVF gene located on chromosome 16 for Familial Mediterranean Fever and its different types of mutations were identified (3). This gene produces a protein called pyrin, or marenosttrin, which predetermines the development of the disease. However, it is still unclear what factors trigger the development of attacks and determine their frequency. The fact that attacks of FMF have no periodicity and regularity, leads to the idea for the existence of specific extraneous or environmental factors that may precipitate attack. In the literature various attack precipitants are discussed (3,7,11,14). Among them are foods rich in fat, emotional stress, physical activity, cold, climate and menstruation. Several investigators reported reduction of attack frequency after the restriction of fat food consumption (2,11). However, the data about diet modification and its effectiveness for attack frequency reduction are controversial (9).



Schwartz pointed an example of a woman whose attacks started immediately before menstruation (15). Also case of a woman completely responding to the short-term colchicine treatment before first signs of menstruation was described in the literature (16). In many women the attacks disappear during pregnancy and occur again after delivery (2). Shaar and Armenian provided data on the relation of the severity of attacks to menstruation (17). Hormonal disturbances cannot account fully for the development of attacks as they are described in males, children and menopausal women; however, hormonal fluctuations still should be considered as possible attack precipitants. Many patients reported that prolonged standing or walking leads to the development of joint attacks involving lower extremities, and several patients have associated emotional stress as a precipitating factor (11).

Patients affected with FMF need continuous treatment and are at risk of amyloidotic complications. During the attacks they usually are unable to maintain their normal level of social activity and are in need of care, which creates a burden not only on the health care system but also on a society as whole. The average duration of attacks is 24-96 hours. The protracted arthritic attacks last for weeks or even months. The frequency of attacks ranges from weekly to one per year. Thus, taking into account that Familial Mediterranean Fever is a lifelong disease, manifesting with frequent attacks, which keeps patients from their usual lifestyle for days, or even for weeks, and creates an economic burden on the society, the determination of the precipitants for FPP attacks is essential for prediction and prevention of attacks.

There is evidence that the prevalence rate of FMF for Armenians ranges from 1 per 1,000 to 5 per 1,000 and the frequency of the affected gene is the highest among Armenians living in Armenia (5,6). These data provide the rationale for performing the proposed study in Armenia. Most of the studies conducted in Armenia focused on the pathogenesis of the disease. The literature

shows that there is a big gap in the knowledge about the attack precipitating factors for FMF. No studies exploring the possible attack precipitants have been done. This study intends to identify attack-precipitating factors for Familial Mediterranean Fever for further prevention of attacks.

### ***Methods/study design***

The case-crossover design, a variation of the case control study design, is proposed. The case-crossover study design facilitates comparison of exposures that vary over time for an individual. It enables the use of the same people as cases and controls. Using the same people in case and control groups allows to have highly matched comparison sets, thus minimizing potential confounding.

### ***Study population***

Verification of the FMF diagnosis at the genetic level is available in Armenia only by using the services of the CMG of the National Academy of Sciences of Republic Armenia. Its database includes more than 1,500 patients with genetically verified diagnosis. The database contains not only the results of the genetic test, but also the clinical diagnosis. Patients included in the roster are followed-up by the rheumatologist at the Center of Medical Genetics.

Cases are defined as patients with genetically verified diagnosis of FMF during or immediately after the FMF attack. Controls are the same patients at a random day during an attack free period. Children will also be included since about 50% of the patients comprise children. Mothers will complete the questionnaire instead of children.

Exclusion criteria are:

- Patients with mental disorders

- Refusal to participate

### *Sample size*

The sample size calculation was accomplished using the EpiInfo statistical package. Defining the values for  $\alpha=0.05$  (two-sided),  $\beta=0.2$ , and assuming that the difference in exposure (namely, exposure to the high-fat diet) among cases and controls is 15 percent, the required sample size was calculated as equal to 300 cases and 300 controls. Taking into account that the case-crossover study design employs the same people as cases and controls the total number of participants will be 300.

The sample size of 300 cases and 300 controls will allow determining the presence of association between the development of attacks and possible attack precipitants. For determination of the interactions between the various attack precipitants it is required to increase sample size by the factor of variables included in the analysis.

$$\alpha = 0.05 \text{ (two-sided)}$$

$$\beta = 0.2$$

$$d \text{ (difference in exposure between cases and controls)} = 15\%$$

$$n=300$$

$$\text{Power} = 1 - \mathbf{b} = 0.8$$

Although the calculated sample size is equal to 300 participants, it is proposed to select 350 participants to assure the needed sample size in case of dropouts, or refusals during the study.

### ***Study instrument***

The study instrument is a self-administered questionnaire of 53 questions. The self-administered format was chosen for the questionnaire, because it will be not feasible to meet the patient exactly on the day of the attack. The questionnaire will be provided to the cases (patients during or immediately after the attack) and to the controls (the same patients on the random days in attack free period). The instrument consists of demographic questions, questions on the disease history, questions on the hormonal status, questions on the general lifestyle and questions on the lifestyle regarding the past two-three days period. It also contains questions regarding changes in attack frequency during traveling outside of Armenia for a long time.

The aim of the questionnaire is to compare patients' exposure to various factors during the random day in the attack free period (controls) and during the 2-3 day period prior to the attack (cases). That allows the calculation odds ratios and to determine whether there is an association (positive or negative) between exposure to several attack precipitants and attack occurrence. The exploration of patients' lifestyle during preceding 2-3 days period is aimed to reveal some extraneous factors that have adverse effect on patients health and precipitate attacks. The questionnaire has been pre-tested on the patients from the Center of Medical Genetics resulting in minor changes. The average duration of the questionnaire's completion during the pre-test was about 20 minutes.

### ***Data collection***

Study participants will be recruited from the roster of patients with genetically verified diagnosis from the Center of Medical Genetics. The systematic random sampling technique will be applied for selection of the sample of 350 patients.

At the random day in attack free period participants will complete the questionnaire and serve as control group and during or immediately after the attack they will fill in the same questionnaire as cases.

The selection of the study population from the roster will be done with assistance of the consultant from the Center of Medical Genetics hired for the project. The questionnaires will be distributed and collected by the project assistant.

The program assistant at the random day in attack free period will get in touch with identified participants, arrange a meeting with them and pay a visit. During the visit s/he will explain the purpose of the study and provide participants with consent form, which includes the information about the goals of the study, who is conducting the study, procedures, risks, benefits, confidentiality and anonymity assurance, voluntariness and whom to contact in case of questions or disrespectful attitude.

Afterwards the participant will complete the questionnaire as a control. The project assistant will leave several copies of the same questionnaire that should be completed during the attacks. After three months the project assistant will again arrange a meeting with participants and collect back completed questionnaires. During these three months the project assistant will call several times to remind the patients to complete the questionnaires during attacks. The project assistant will instruct every tenth patient to contact with him/her during one of the attacks. During the attack the program coordinator along with project assistant will visit patients in order to validate the attack.

The Center of Health Services Research and Development of the American University of Armenia is available to conduct the study in cooperation with the Center of Medical Genetics. The initial agreement for the joint research between two agencies is attained.

### *Data analysis*

The statistical analysis will be carried out by Stata statistical package. The dependent variable is defined as the incidence of attacks and the independent variables are high-fat diet, physical stress, emotional stress, cold, climate and menstruation. It is proposed to use:

- Chi-square test and to determine the odds ratios with 95 % confidence intervals
- Chi-square test for detection of associations between different types of mutations and various attack precipitants
- Conditional logistic regression

In case if the association will be detected it is proposed to increase the sample size by the factor of variables included in the analysis and to conduct logistic regression analysis.

### *Study limitations*

The study limitations are:

- Recall bias – typical for case-control studies. This type of bias is minimized in the study because most of the questions refer to the events during the immediate 2 or 3 days.
- Another concern is that usually people try to be consistent in their responses. As the questionnaire will be given to participants at least two times (one time as case and one time as control), they will, probably, tend to answer the questions in the same way as the first time.
- Instrumental bias – though the questionnaire was pre-tested on 6 patients, it still can be a source of bias.

- The price for the genetic test for verification of the Familial Mediterranean Fever diagnosis is about 30 US dollars, which is expensive for the general Armenian population. The concern is that the roster of patients from the Center of Medical Genetics comprises mostly patients who are in a high-income bracket. This could negatively affect the generalizability of the study results.
- Because only the Center of Medical Genetics has the capabilities for genetic verification of FMF diagnosis in Armenia and it located in Yerevan, patients from the backcountry districts may not able to pass the genetic test, thus the generalizability of the study will be limited.

### *Time frame*

The duration of the study is anticipated to be 8 months. During the first month the project consultant, hired from the Center of Medical Genetics, along with the project assistant will select participants from the roster of the patients. Afterwards, the project assistant will arrange a meeting with participants. Later the participants will be provided with the questionnaire that they will complete as controls. Filled questionnaires will be collected back. Afterwards the program assistant will give to participants few copies of the same questionnaires, which will be filled during or immediately after the attacks. Each meeting will take about one hour including transportation time. It is proposed that during an average day the project assistant will conduct on average 5 visits. Taking into account that the total number of participants is 300 and that not all of them live in Yerevan, the office assistant will perform 300 visits during 3 months period. At the end of the third month the project assistant will start collection of the questionnaires filled during the attack period. S/he will call patients, arrange a meeting with them and collect back the

questionnaire filled during the attack periods. Collection back of the completed questionnaires will last three month in order to provide participants involved in the study at the end of the third month opportunity to fill in the questionnaire during at least one attack. The whole period of data collection will last 6 months.

Taking into account the frequency of attacks varies from patient to patient it is predicted that on the average patients will have at least 3-4 attacks per year. This will allow for a minimum 300 questionnaires to be completed by the cases if every participant will have only one attack during 3 months period. At the end of the sixth month it proposed to complete the data collection. Simultaneously with data collection, data entry will start. The project assistant will do first data entry. After that the data analyst will do the double entry to minimize the data entry bias. The data entry will last until the end of the seventh month. The total number of questionnaires will be at least 600. Assuming that the entry of one questionnaire will take 10 minutes, it is expected that the doubled entry of at least six hundred questionnaires will be completed upon the end of the seventh month.

During the first half of the eighth month the data analysis will be carried out. It is proposed to write the final report during the second half of the eighth month.

After the completion of the study if the positive association between the occurrence of attacks and various attack precipitants will be detected it is proposed to recommend the research using the same study population and the same study instrument. Inclusion of all patients from the roster will allow the investigation of interactions between already established attack precipitants and to create a multiple logistic regression model for prevention of attacks. (See Appendix 1)



### ***Ethical considerations***

The proposal has been submitted to the Institutional Review Board/Committee on Human Research of the American University of Armenia and received approval as a grant proposal. It poses minimal risk for the study participants; the information gathered during the study will be useful in defining the triggering mechanisms for the development of attacks.

The unique identifiers given to each participant will the confidentiality of the subjects. Only study investigators, namely co-primary investigators, program coordinator, program assistant, project consultant and data analyst, will have an access to the identification numbers of participants.

### ***Budget***

The estimated expenses for implementation of the proposed study are \$25,270. Out of this amount about 56 % comprise salaries. The operational costs are covered by 13 % of the total expenses; about 26 percent compose general administrative expenses and the remainder 5 percent of the total budget cover unexpected expenditures. (See appendix 2)

### ***Personnel responsibilities***

The program coordinator is responsible for the study conduction, management and administrative duties. The program coordinator will perform the data analysis and will be responsible for the preparation of the final report.

The project assistant will be responsible for data collection and data entry. S/he will assist in ongoing daily activities. S/he will coordinate the driver's activities.

The consultant from the Center of Medical Genetics will assist in the selection of the sample. S/he will participate in data analysis. The accounting consultant will be in charge of account preparation and preparation of financial statements.

The driver/office assistant will be responsible for transportation, maintenance of the office supplies, will perform routine everyday activities under the coordination of the project assistant.

**References**

1. Pras E, Aksantijevich I, Gruberg L, Balow J, Prosen L, Dean M et al. Mapping of a gene causing Familial Mediterranean Fever to the short arm of chromosome 16. *New Eng J Med* 1992 Jun 326 (4):1509-1513.
2. Samuels J, Aksantijevich I, Torosyan Y, Centola M, Deng Z, Sood R, Kastner DL. Familial Mediterranean Fever at the Millennium. Clinical spectrum, ancient mutations, and a survey of 100 American Referrals to the National Institute of Health. *Medicine (Baltimore)*. 1998 Jul; 77(4):268-97
3. Kastner DL. Familial Mediterranean Fever: The Genetics of Inflammation. *Molecular Genetics in Clinical Practice*. Hospital practice.  
<http://www.hosppract.com/genetics/9804gen.htm>
4. Armenian HK, Sha'ar H. Epidemiologic observations in familial paroxysmal polyserositis. *Epidemiologic reviews*. 1986,vol. 8, pp.106-116.
5. NIH Press release. NIH leads international group that identifies gene for Familial Mediterranean Fever. Mutations date back to Biblical times.
6. Shohat M, Danon Y, Rotter J. Familial Mediterranean Fever: Analysis of inheritance and concurrent linkage data. *Am J Med Gen* 1992, 44:183-188.s  
<http://www.nih.gov/news/pr/aug97/niams-21.htm>
7. Torosyan Y. Periodic disease in Armenia. Mode of inheritance and concepts of ethiopathogenesis. Yerevan, 1996
8. Ben-Chetrit E, Levy M. Familial Mediterranean Fever. *Lancet* 1998; 351:659-64.

9. Schwabe AD, Peters RS. Familial Mediterranean Fever in Armenians. Analysis of 100 cases. *Medicine (Baltimore)*.1974 ; 55 (6): 453-62.Meyerhoff J. Mediterranean Fever, Familial. *eMedicine Journal*, December 5 2000, Volume 1, Number 12.  
<http://www.emedicine.com/med/topic1410.htm>
10. Bennett: Cecil Textbook of Medicine, 20th ed., Copyright © 1996 W. B. Saunders Company. Familial Mediterranean fever.  
[http://www.brown.edu/Administration/Emergency\\_Medicine/emr/pages/fmf.html](http://www.brown.edu/Administration/Emergency_Medicine/emr/pages/fmf.html)
11. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. *American Journal of Medicine*. 1967; 43: 227-53
12. Ben-Chetrit E, Levy M. Colchicine: 1998 update. *Semin Arthritis Rheum* 1998 Aug;28(1):48-59
13. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. *Pharmacotherapy* 1991; 11(3):196-21.
14. Armenian H. K. Genetic and environmental factors in the aetiology of Familial Paroxysmal Polyserositis. An analysis of 150 cases from Lebanon. *Tropical and Geographical Medicine*, 34 (1982):183-187.
15. Schwartz J. Periodic peritonitis, onset simultaneously with menstruation. *Vol. 53 (2): 407-12*
16. Milano AM. Familial Mediterranean fever associated with menstruation. Efficacy of intermittent colchicine therapy. *Am J Gastroenterol*, Oct 1981, 76(4):363-4.
17. Shaar K, Armenian H. The relationship of stress to severity of attacks in cases of Familial Paroxysmal Polyserositis: an exploratory study.

*Timeframe*

Activity	Month								
	1st	2nd	3rd	4th	5th	6th	7th	8th	
								1st half	2nd half
Hiring the staff, preparation of supplies, copies of questionnaires, logistics									
Selection of participants from the roster									
Data collection									
Data entry									
Data analysis									
Preparation of the final report									

**Budget**

	\$	Duration	Total
<b>Personnel</b>			
Co-primary investigator (CHSR)	\$400 per day	7 days	\$2 800
Co-primary investigator (CMG)*	\$100 per month	7 days	\$700
Program coordinator*	\$650 per month	8 months	\$4 800
Program assistant*	\$450 per month	8 months	\$3 200
Project consultant (CMG)*	\$300 per month	2 months	\$800
Data analyst*	\$300 per month	1 month	\$300
Accounting consultant*	\$15 per day	10 days	\$150
Driver/office assistant*	\$200 per month	8 months	\$1 600
<b>Subtotal</b>			<b>\$14 350</b>
<b>Operational costs</b>			
Communications	\$70	8 months	\$560
Office supplies	\$40	8 months	\$320
Car rental/maintenance	\$200	8 months	\$1 600
Fuel	\$100	8 months	\$800
<b>Subtotal</b>			<b>\$3 280</b>
<b>Total</b>			<b>\$17 630</b>
Unexpected expenses	5% of the total		\$882
<b>Grand Subtotal</b>			<b>\$18 512</b>
General Administrative Expenses	36,5% of total expenses		\$6 757
<b>Grand Total</b>			<b>\$25 270</b>

\*- Salaries include taxes

## QUESTIONNAIRE

**ID Number:** \_ \_ \_ \_ \_

Date: \_ \_ \_ \_  
           D D M M Y Y

Digit 1-2	Code of site
Digit 3-6	Number of interview

### *Demographic questions*

1. First name \_\_\_\_\_ Last name \_\_\_\_\_
2. Gender: \_\_\_\_\_ Male    \_\_\_\_\_ Female
3. Date of birth: \_ \_ \_ \_ \_  
                                   DD MM YY
4. What is your ethnical background? \_\_\_\_\_
5. Are you currently employed?
  - a) Yes (please, indicate your major)
  - b) No
6. Marital status:
  - a) Married
  - b) Single
  - c) Divorced
  - d) Widowed
7. Do you have brother(s) or sister(s)?
  - a) Yes
  - b) No \_\_\_\_\_ go to Q9
8. Do/Does they/he/she suffer from the Familial Mediterranean Fever?
  - a) Yes
  - b) No
  - c) Don't know
9. Does/did any of your other relatives also suffer from the Familial Mediterranean Fever?
  - a) Yes
  - b) No
  - c) Don't know

10. Do you have children?  
a) Yes  
b) No

*Questions on disease history*

11. At what age did you have the first attack? \_\_\_\_\_
12. At what age was your disease first medically diagnosed? \_\_\_\_\_
13. What type was your first attack?  
a) Abdominal  
b) Pleuritis  
c) Synovitis  
d) Skin manifestations  
e) Amiloidosis first  
f) Mixed (Combination of symptoms)  
g) Other, please describe \_\_\_\_\_
14. During last two years on the average, how many attacks do you have per year?  
a) Less than 5  
b) 5-10  
c) 10-20  
d) More than 20
15. What kind of attacks have you had during last two years? (*Check all that apply*)  
a) Abdominal  
b) Pleuritis  
c) Synovitis  
d) Skin manifestations  
e) Mixed (Combination of symptoms)  
f) Other, *please describe* \_\_\_\_\_
16. If you have attacks that affect your joints, which joints are involved?  
a) Knee  
b) Ankle  
c) Hip  
d) Shoulder  
e) Combination of above mentioned  
f) Other, specify \_\_\_\_\_  
g) Usually I don't have synovial attacks \_\_\_\_\_ go to Q18
17. What kind of joint attacks do you have?  
a) Acute (attacks last from 12 to 72 hours)  
b) Subacute (attacks last up to week)  
c) Protracted (attacks last up to months)



18. Do you receive any treatment?  
 a) Yes  
 b) No \_\_\_\_\_ go to Q20
19. What kind of treatment do you receive?  
 a) NSAID (like “Voltaren”, “Aspirine”, etc.)  
 b) Steroids  
 c) Oral contraceptives  
 d) Colchicine  
 e) Other, specify \_\_\_\_\_
20. Do you take Colchicine ?  
 a) Yes  
 b) No \_\_\_\_\_ go to Q23
21. How often do you take Colchicine and at what dose?  
 a) I take Colchicine when I have symptoms (specify dose in milligrams \_\_\_\_\_)  
 b) I take Colchicine every day (specify dose in milligrams \_\_\_\_\_)
22. Does the treatment with Colchicine reduce the frequency of attacks?  
 a) Yes  
 b) No
23. Have you ever been told that you have protein in your urine (proteinuria)?  
 a) Yes  
 b) No -----go to Q25  
 c) Don't know -----go to Q25
24. At what age did you first have protein in your urine? Specify age: \_\_\_\_\_

### *Lifestyle questions*

25. How often do you (eat foods rich in fats) use fat food (like pork, lard, sour cream, etc.)?  
 a) Every day  
 b) 2-3 times per week  
 c) 2-3 times per month  
 d) Once per month  
 e) Don't know
26. Have you ever smoked cigarettes?  
 a) Yes  
 b) No
27. Do you smoke currently?  
 a) Yes  
 b) No -----go to Q29

28. How many cigarettes do you smoke per day?
- Less than 10
  - 10-20
  - More than 20
29. Do you do physical exercises regularly?
- Yes
  - No \_\_\_\_\_ go to Q32
30. When you exercise, how many minutes do you usually engage in the activity?
- 5-10
  - 10-20
  - 20-30
  - 30 and more
31. How often do you exercise?
- Every day
  - 2-3 times per week
  - Several times per month

***Lifestyle questions regarding last 2-3 days period***

32. During last two days did you consume:
- |              |        |       |
|--------------|--------|-------|
| • Sausage    | a) yes | b) no |
| • Pork       | a) yes | b) no |
| • Lard       | a) yes | b) no |
| • Whole milk | a) yes | b) no |
| • Butter     | a) yes | b) no |
| • Sour cream | a) yes | b) no |
| • Ice cream  | a) yes | b) no |
| • Pastry     | a) yes | b) no |
| • Eggs       | a) yes | b) no |
33. Did you consume alcohol during the past two days?
- Yes
  - No \_\_\_\_\_ go to Q35
34. How much alcohol did you consume?
- Less than 100g of vodka, cognac, etc.
  - 100-200 g of vodka, cognac, etc.
  - More than 200g of vodka, cognac, etc.
  - A glass of beer or wine
  - More than one glass of beer or wine

35. During the past two days did you have positive emotional stress (like anniversaries, wedding, etc.)?  
a) Yes  
b) No
36. During the past two days did you have negative emotional stress (like examinations, personal danger, acute grief, etc.)?  
a) Yes  
b) No
37. During the past two days do you have excessive physical activity?  
c) Yes  
d) No
38. Did you have a cold or flu during past week?  
a) Yes  
b) No
39. Have you ever traveled outside Armenia for a long time (more than 6 months)?  
a) Yes  
b) No -----go to Q42
40. Have you noticed any changes in the frequency of attacks during these visits?  
a) Yes  
b) No \_\_\_\_\_ go to Q42
41. The frequency of attacks:  
a) Increased  
b) Decreased
42. Have you noticed any seasonal differences in frequency of attacks?  
a) Yes  
b) No -----go to Q44
43. When your attacks are more frequent?  
a) Spring  
b) Summer  
c) Autumn  
d) Winter  
e) No seasonal differences

***Questions on menstrual cycle (Female only)***

44. When was your menarche? \_\_\_\_\_
45. What is the duration of your menstrual cycle?  
 a) Please, specify \_\_\_\_\_  
 b) Not applicable (no menses)
46. How many days past since the first day of your last menstrual bleeding? \_\_\_\_\_
47. Have you ever noticed the occurrence of attacks immediately before the onset of menses?  
 a) Yes  
 b) No
48. Did you note any changes in attacks' frequency during pregnancy?  
 a) Yes  
 b) No \_\_\_\_\_ go to Q50  
 c) Not applicable \_\_\_\_\_ go to Q50
49. The frequency of attacks during pregnancy:  
 a) Increases  
 b) Decreases

***Questions on warning signs***

50. Usually prior the beginning of the attack do you feel any of the following warning signs?  
 (Check all that apply).  
 a) Chills  
 b) Local pain in humeral joints  
 c) Myalgia  
 d) Diarrhea  
 e) Constipation  
 f) Meteorism  
 g) Mood changes  
 h) Other, specify \_\_\_\_\_  
 i) I don't feel any warning signs \_\_\_\_\_ go to Q53
51. How long before an attack do you feel the warning symptoms?  
 a) 2-3 hours  
 b) 8-10 hours  
 c) 1-2 days  
 d) Other, specify \_\_\_\_\_  
 e) Don't have any warning symptoms

52. Do you feel any other warning signs?

- a) Yes, specify \_\_\_\_\_
- b) No

53. Is there anything you would like to add that has not been mentioned in this questionnaire?

- a) Yes, specify, \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_
- b) No

Thank you.



10. „áòù »ñ»É³ (Ý»ñ) áôÝ»±ù.

1. ²á
2. àã

**Ð²ðò°ð ÐÆì ²Û „àòÁÚ²Û ä²ì ØàòÁÚ²Û ì °ð² ´°ðÚ²È**

11. à±ñ ì³ ñÇùáòÛ ì³ »ÕÇ áôÝ»ó³ í³ é³ ÇÇÝ Ýáã³ Ý \_\_\_\_\_

12. àñ ì³ ñÇùáòÛ³ é³³ ÇÇÝ³ Ý.³ Û Ò»½ Ûáì³ Èì áñáßì »ó <<ã³ ñμ»ñ³ Ì³ Ý ÑÇì³ Ý¹áóÁáôÝ>>\_\_\_\_\_

13. Æ±Ýã ì³ ÇãÇ ìñ³ é³ ÇÇÝ Ýáã³ Ý.

1. àñáì³ ÛÝ³ ÛÇÝ ó³ í³ »ñ
2. Íñí ù³ í³ Ý¹³ Ì³ ÛÇÝ ó³ í³ »ñ
3. Ðá¹³ ÛÇÝ ó³ í³ »ñ
4. Ø³ ßíÇ³ Èì³ Ñ³ ñáòÛ/ó³ Ý³ í³ áñáòÛ
5. ²ÛÇÉáÇ¹á½ (»ñÇì³ ÛÝ»ñÇ³ Èì³ Ñ³ ñáòÛ)
6. Ê³ éÁ³ (Èì³ ÝÇß»ñÇ Ñ³ Û³ Í óáóÁÛ³ Ûμ)
7. ²ÙÉ, Ýß»ù\_\_\_\_\_

14. ì³ »ñÇÇÝ »ñí áò ì³ ñí³ ÁÝÃ³ óùáòÛ ÛÇÇÝáòÛ ù³ ÝÇ± Ýáã³ »ù áôÝ»ó»É.

1. 5-Çó ùÇã
2. 5-10
3. 10-20
4. 20-Çó³ í³ »ÉÇ

15. ì³ »ñÇÇÝ »ñí áò ì³ ñí³ ÁÝÃ³ óùáòÛ ÑÇÛÝ³ Ì³ ÝáòÛ ÇÝã ì³ ÇãÇ Ýáã³ Ý»ñ »±ù áôÝ»ó»É.

1. àñáì³ ÛÝ³ ÛÇÝ (éáòñ ó³ í³ »ñ áñáì³ ÛÝÇ ßñÇ³ ÝáòÛ)
2. Íñí ù³ í³ Ý¹³ Ì³ ÛÇÝ (éáòñ ó³ í³ »ñ Íñí ù³ í³ Ý¹³ Ì³ Ç ßñÇ³ ÝáòÛ)
3. Ðá¹³ ÛÇÝ (ó³ í³ »ñ Ñá¹»ñÇ ßñÇ³ ÝáòÛ)
4. Ø³ ßíÇ³ Èì³ Ñ³ ñáòÛ
5. Ê³ éÁ³ (Èì³ ÝÇß»ñÇ Ñ³ Û³ Í óáóÁáôÝ)
6. ²ÙÉ, Ýß»ù\_\_\_\_\_

16. Đá<sup>13</sup> ó<sup>3</sup> í »ñÇ Á<sup>3</sup> Û<sup>3</sup> Ý<sup>3</sup> Í á±ñ Ñá<sup>1</sup>»ñÝ »Ý<sup>3</sup> È<sup>3</sup> Ñ<sup>3</sup> ñí áóÙ.
1. êñáoÝùÃ<sup>3</sup> Ã<sup>3</sup> ÛÇÝ Ñá<sup>1</sup>
  2. Ì Ý<sup>3</sup> Ñá<sup>1</sup>
  3. Í áÝù<sup>3</sup> ½<sup>1</sup>ñ<sup>3</sup> ÛÇÝ Ñá<sup>1</sup>
  4. ´<sup>3</sup> ½<sup>3</sup> ÛÇÝ Ñá<sup>1</sup>
  5. Ûßí<sup>3</sup> Í Ñá<sup>1</sup>»ñÇ Ñ<sup>3</sup> ÛÍ óáoÃÙáoÝ
  6. ²ÙÉ, Ýß»ù \_\_\_\_\_
  7. °è ã»Ù áóÝ»ÝáoÙ Ñá<sup>13</sup> ó<sup>3</sup> í »ñ
17. Æ±Ýã ì ÇãÇ Ñá<sup>13</sup> ó<sup>3</sup> í »ñ »ù áóÝ»ÝáoÙ.
1. éáoñ (12-72 Á<sup>3</sup> Û ì ´´áoáoÃÙ<sup>3</sup> Ûμ)
  2. °ÝÃ<sup>3</sup> éáoñ (ÙÇÝã´´ Û»Í ß<sup>3</sup> μ<sup>3</sup> Ã ì ´´áoáoÃÙ<sup>3</sup> Ûμ)
  3. °ñ<sup>3</sup> ñ<sup>3</sup> ì ´´ (ì ´´áoÙ »Ý<sup>3</sup> ÛÇèÝ»ñ)
18. ,áoù è<sup>3</sup> Ýáo±Ù »ù máóÁáoÙ á<sup>3</sup> ñμ»ñ<sup>3</sup> Í<sup>3</sup> Ý ÑÇí<sup>3</sup> Ý<sup>1</sup>áoÃÙ<sup>3</sup> Ý<sup>3</sup> í<sup>3</sup> á<sup>3</sup> Í óáoÃÙ<sup>3</sup> Ûμ.
1. ²Ùá
  2. àã \_\_\_\_\_ ²Ùò°ø **Đ<sup>3</sup> ñó 20**
19. Æ±Ýã máóÁáoÙ »ù è<sup>3</sup> ÝáoÙ á<sup>3</sup> ñμ»ñ<sup>3</sup> Í<sup>3</sup> Ý ÑÇí<sup>3</sup> Ý<sup>1</sup>áoÃÙ<sup>3</sup> Ý<sup>3</sup> í<sup>3</sup> á<sup>3</sup> Í óáoÃÙ<sup>3</sup> Ûμ  
Ý»ñ<sup>3</sup> ÛáoÙè.
1. àã ÑánÙáÝ<sup>3</sup> ÛÇÝ Ñ<sup>3</sup> Í<sup>3</sup> máñμάù<sup>3</sup> ÛÇÝ ÛÇÇáoÝ»ñ (ùñÇÝ<sup>3</sup> Í<sup>3</sup> Ý<sup>3</sup> É. ÇÝ, μñáoý»Ý, ÇÝ<sup>1</sup>áÙ»ì<sup>3</sup> óÇÝ, í áÉì<sup>3</sup> ñ»Ý)
  2. ĐánÙáÝ<sup>3</sup> É Ñ<sup>3</sup> Í<sup>3</sup> máñμάù<sup>3</sup> ÛÇÝ ÛÇÇáoÝ»ñ (èì »ñáÇ<sup>1</sup>Ý»ñ, ùñÇÝ<sup>3</sup> Í<sup>3</sup> áñ»<sup>1</sup>ÝÇ½áÉáÝ)
  3. Đ<sup>3</sup> Í<sup>3</sup> μ»ÕÙÝ<sup>3</sup> í áñÇã Ñ<sup>3</sup> μ»ñ
  4. Í áÉÈÇóÇÝ
  5. ²ÙÉ, Ýß»ù \_\_\_\_\_
20. ,áoù è<sup>3</sup> Ýáo±Ù »ù Í áÉÈÇóÇÝ.
1. ²Ùá
  2. àã \_\_\_\_\_ ²Ùò°ø **Đ<sup>3</sup> ñó 23**



21. àñù³ Ý Ñ³ ×³ È · Ç±Ýà ¹»Õ³ ã³ ÷áí »ù ëì ³ ÝáòÙ ÍáÉÈÇóÇÝÁ
1. °ë ÁÝ¹áóÝáòÙ »Ù ÍáÉÈÇóÇÝÁ Ýáã³ ÌÇ ëì ½μáòÙ (Ýß»ù ¹»Õ³ ã³ ÷Á)\_\_\_\_\_
  2. °ë ÁÝ¹áóÝáòÙ »Ù ÍáÉÈÇóÇÝÁ ³ Ù»Ý ùñ³ ³ Ýí ³ È Ýáã³ ÌÇ ³ éí ³ ÌáóÁÌáóÝÇó (Ýß»ù ¹»Õ³ ã³ ÷Á)\_\_\_\_\_
22. ÍáÉÈÇóÇÝÁí μáòÁÙ³ Ý ³ ñ¹ÌáóÝúáòÙ Ýí ³ ½»É ç, ³ ñ¹Ìáò, Ýáã³ Ý»ñÇ Ñ³ ×³ È³ Í³ ÝáóÁÌáóÝÁ.
1. ²Ùá
  2. àã
23. Ò»½ Úáí »ñμ·ç Ñ³ Ìí Ý³ μ»ñí »±É ç ëáÇí ³ Íáóó¹ (μ»Éáí) Ù»½áòÙ (ãñáí »ÇÝáóñÇ³)
1. ²Ùá
  2. àã \_\_\_\_\_ ²Ùò°ø **Ð³ ñó 25**
  3. â· Çí »Ù \_\_\_\_\_ ²Ùò°ø **Ð³ ñó 25**
24. àñì ì ³ ñÇùáòÙ ç ³ é³ çÇÝ ³ Ý· ³ Ù ³ Èì áñáÍ »É áñáí »ÇÝáóñÇ³ Ý (ëáÇí ³ ÍáóóÇ/μ»Éáí Ç ³ éí ³ ÌáóÁÌáóÝÁ Ù »½áòÙ).\_\_\_\_\_

**Ð²ðò°ð ²äð°È²È°ðäÆ ì °ð² °ðÚ²È**

25. àñù³ Ý Ñ³ ×³ È »ù ù· ì ³ · áñÍ áòÙ ÌáóÕ³ ÈÇ ëÝáóÝ¹ (ùñÇÝ³ Í¹ Èá½Ç ÙÇë, ×³ ñã, á³ Õã³ Õ³ Ì)
1. ²Ù»Ý ùñ
  2. Þ³ μ³ ÁÁ 2-3 ³ Ý· ³ Ù
  3. ²ÙÇëÁ 2-3 ³ Ý· ³ Ù
  4. ²ÙÇëÁ 1 ³ Ý· ³ Ù
  5. â· Çí »Ù
26. °ñμ·ç Í È»±É »ù.
1. ²Ùá
  2. àã

27. Ù»ñí³ ÙáóÙè Í Èáó±Ù »ù.  
 1. ²Ùá  
 2. à ã \_\_\_\_\_ ²Ùò°ø **Đ³ ñó 29**
28. ØÇçÇÝáóÙ ù³ ÝÇ± èÇ. ³ ñ»í »ù Í ÈáóÙ ùñí³ ÁÝÃ³ óùáóÙ.  
 1. 10-Çó ã³ Í³ è  
 2. 10-20  
 3. 20-Çó ³ í »ÉÇ
29. ²ñ¹Ùáù ½µ³ Őí áó±Ù »ù Ù³ ñÙÝ³ Ù³ ñ½áóÃÙ³ Ùµ¹Í³ ÝáÝ³ í áñ Í »ñááí .  
 1. ²Ùá  
 2. àã \_\_\_\_\_ ²Ùò°ø **Đ³ ñó 32**
30. à±ñù³ Ý Ñ³ ×³ È »ù ½µ³ Őí áóÙ Ù³ ñÙÝ³ Ù³ ñ½áóÃÙ³ Ùµ.  
 1. ²Ù»Ý ùñ  
 2. ƒ³ µ³ ÃÁ 2-3 ³ Ý. ³ Ù  
 3. ²ÙÇèÁ 3-4 ³ Ý. ³ Ù
31. ø³ ÝÇ± ñáá» »ù í ñ³ Ù³ ¹ñáóÙ Ù³ ñÙÝ³ Ù³ ñ½áóÃÙ³ ÝÁ.  
 1. 5-10 ñáá»  
 2. 10-20 ñáá»  
 3. 20-30 ñáá»  
 4. 30 ñáá»Çó °³ í »ÉÇ

**Đ²ðò°ð ì °ðæÆÙ 2-3 úðì ² ²äð°È²Í °ðäÆ ì °ð² °ðÚ²È**

32. ì »ñçÝ 2-3 ùñí³ ÁÝÃ³ óùáóÙ ù. ³ í áñÍ »É »±ù, ³ ñ¹Ùáù, Ñ»í °Ù³ È èÝÝ¹³ ÙÃ»ñùÝ»ñÁ.

- |              |        |       |
|--------------|--------|-------|
| a) °ñßÇÍ     | 1. ²Ùá | 2. àã |
| b) È á½Ç ÙÇè | 1. ²Ùá | 2. àã |
| c) Ő³ ñá     | 1. ²Ùá | 2. àã |
| d) Í³ Ã      | 1. ²Ùá | 2. àã |
| e) Í³ ñ³.    | 1. ²Ùá | 2. àã |
| f) ÃÁí³ è»ñ  | 1. ²Ùá | 2. àã |
| g) È ÙáñáŐáÝ | 1. ²Ùá | 2. àã |
| h) Òáó       | 1. ²Ùá | 2. Æã |

33. ì »ñçÝ 2-3 ùñí ³ ÁÝÃ³ òùáòÙ ù. ³ ì áñÍ »É »±ù, ³ ñ¹Ùáù, ³ ÉÍ áÑáÉ.  
 1. ²Ùá  
 2. àã \_\_\_\_\_ ²Ùò°ø Ð³ ñó 35
34. Æ±Ýã ù³ Ý³ Í áòÃÙ³ Ùμ ³ ÉÍ áÑùÉ »ù ù. ì ³. áñÍ »É.  
 1. 100 · ñ³ ÙÇó á³ Í³ è (ùÕÇ, Í áÝÙ³ Í)  
 2. 100-200 · ñ³ Ù (ùÕÇ, Í áÝÙ³ Í)  
 3. 200 · ñ³ ÙÇó ³ í »ÉÇ (ùÕÇ, Í áÝÙ³ Í)  
 4. Ø»Í · ³ í ³ Æ · ³ ñ»çáòñ Í³ Ù · ÇÝÇ  
 5. Ø»Í · ³ í ³ ÆÇó ³ í »ÉÇ · ³ ñ»çáòñ Í³ Ù · ÇÝÇ
35. ì »ñçÝ 2-3 ùñí ³ ÁÝÃ³ òùáòÙ áóÝ»ó»±É »ù, ³ ñ¹Ùáù, ¹ñ³ Í³ Ý Ñáò½»ñ  
 (ùñçÝ³ Í³ Ñáμ»ÉÙ³ Ý, Ñ³ ñè³ ÝÇù)  
 1. ²Ùá  
 2. àã
36. ì »ñçÝ 2-3 ùñí ³ ÁÝÃ³ òùáòÙ áóÝ»ó»±É »ù, ³ ñ¹Ùáù, μ³ ó³ è³ Í³ Ý  
 ³ áñáòÙÝ»ñ(ùñçÝ³ Í³ ì Ë áòñ Éáòñ, ùÝÝáòÃÙáóÝÝ»ñ)  
 1. ²Ùá  
 2. àã
37. ì »ñçÝ 2-3 ùñí ³ ÁÝÃ³ òùáòÙ Í³ ì ³ ñ»±É »ù, ³ ñ¹Ùáù, Í³ Ýñ ýÇ½ÇÍ³ Í³ Ý  
 ³ βÉ³ ì ³ Ýù.  
 1. ²Ùá  
 2. àã
38. ì »ñçÝ 2-3 ùñí ³ ÁÝÃ³ òùáòÙ áóÝ»ó»±É »ù, ³ ñ¹Ùáù, Ùñè³ Í áòÃÙáóÝ (- ñçáá½  
 í Ç×³ Í)  
 1. ²Ùá  
 2. àã
39. , áòù »ñμ·¿ Ù»ÍÝ»±É »ù Ð³ Ù³ èì ³ ÝÇó »ñÍ³ ñ Æ³ Ù³ Ý³ Í áí (6³ ÙèÇó ³ í »ÉÇ)  
 1. ²Ùá  
 2. àã \_\_\_\_\_ ²Ùò°ø Ð³ ñó 42



47. Üí³ ï »±É »ù, ³ ñ¹láu, Ýáá³ Ý»ñÇ ³ é³ ç³ óáóÜ ³ ÝÜÇç³ ä»ë ¹³ ßí ³ ÝÇó  
³ é³ ç ï³ Ü ¹³ ßí ³ ÝÇ Á³ Ü³ Ý³ ï:

1. ²lá
2. àā

48. Üí³ ï »±É »ù ³ ñ¹láu Ýáá³ Ý»ñÇ Ñ³ ×³ È³ ï³ ÝáóÄÜ³ Ý ÷ á ÷ á ÈáóÄÜáóÝ  
ÑÖÇáóÄÜ³ Ý Á³ Ü³ Ý³ ï

1. ²lá
2. àā \_\_\_\_\_ ²Üò°ø **Đ³ ñó 50**
3. ĐÖÇáóÄÜáóÝ ä»Ü áóÝ»ó»É \_\_\_\_\_ ²Üò°ø **Đ³ ñó 50**

49. Üáá³ Ý»ñÇ Ñ³ ×³ È³ ï³ ÝáóÄÜáóÝÁ ÑÖÇáóÄÜ³ Ý Á³ Ü³ Ý³ ï.

1. ²×»É çñ
2. Üí³ ½»É çñ
3. ä»ñ ÷ á È í »É

**Đ²ðòð Üàä²Ü°ðÆ Ü²Ê²Üß²ÜÜ°ðÆ ï °ð² °ðÚ²È**

50. éáí áñ³ µ³ ñ áóÝ»Ýáó±Ü »ù, ³ ñ¹láu, Ñ»í ¹Ü³ É Ý³ È³ Ýß³ ÝÝ»ñÁ Ýáá³ ÜÇó  
³ é³ ç. (Ýß»ù ³ ÜÝ³ Ü»ÝÁ, ÇÝá áóÝ»ÝáóÜ »ù)

1. ê³ ñëáóé (¹áÖ)
2. ò³ í µ³ ½í³ ÜÇÝ Ñá¹áóÜ
3. Øí³ Ý³ ÜÇÝ ó³ í
4. öáñÉáóí áóÄÜáóÝ
5. öáñí³ äáóÄÜáóÝ
6. ì üÝ³ Í áóÄÜáóÝ (áñáí³ ÜÝÇ ÷ ùí³ Í áóÄÜáóÝ)
7. î ñ³ Ü³ ¹ñáóÄÜ³ Ý ÷ á ÷ á ÈáóÄÜáóÝ
8. ²lÉ, Ýí³ ñ³. ñ»ù \_\_\_\_\_
9. Ü³ È³ Ýß³ ÝÝ»ñ äçÜ áóÝ»ÝáóÜ \_\_\_\_\_ ²Üò°ø **Đ³ ñó 53**

51. Úáá ½ ħ. 3 óáóÙÇó áñù ±Ý Á Û Ý Í 3 é Ç »ù áóÝ»ÝáóÙ  
Ý Ë Ýß ÝÝ»ñÁ

1. 2-3 Á Û 3 é Ç
2. 8-10 Á Û 3 é Ç
3. 1-2 ùñ 3 é Ç
4. 2ÙÉ, ÝÍ 3 ñ. ñ»ù \_\_\_\_\_

52. ÜÍ 3 Í Ý»ñÇó μ 3 óÇ, áóÝ»Ýáó±Ù »ù, 3 ñ¹Ùáù, áñ¨ 3 ÙÉ Ý Ë Ýß Ý(Ý»ñ)

1. 2Ùá, ÁÍ »ù \_\_\_\_\_
2. àã

53. Í 3 ó Ý 3 Ý ½ Ç±ù, 3 ñ¹Ùáù, áñ¨ 3 μ Ý 3 í »É 3 óÝ»É Ñ 3 ñó 3 ß 3 ñÇÝ

1. 2Ùá  
\_\_\_\_\_  
\_\_\_\_\_
2. àã

ÞÙàðÐ²Í ²ÈàóÁÙàóÙ

**American University of Armenia**  
**Institutional Review Board/Committee On Human Research**

***CONSENT FORM TEMPLATE***

***CHR#***

**Title of Research Project:** Determination of attack precipitating factors for Familial Mediterranean Fever. Case-crossover study.

The Public Health department of the American University of Armenia is conducting a study regarding Familial Mediterranean Fever. The purpose of the study is to obtain the information about factors influencing development of attacks. The interview will take place once in attack free period and once during attack or immediately after it. Every interview will last 20-25 minutes.

We appreciate your participation in this study and your responses are highly valuable to us.

**RISKS/DISCOMFORTS:**

There is no known risk for the participants of the study. The research possesses risk, discomfort and inconvenience the same as encountered in your daily life.

**BENEFITS:**

You will not directly benefit from the participation in this study. However, the information provided by you may help to reveal some additional information about factors influencing development of attacks.

**CONFIDENTIALITY:**

Your name and address or other identifying data will be confidential. Your responses will be accessible only to the Public Health Department of the American University of Armenia.

**VOLUNTARINESS:**

It is your decision whether participate in the study or not. You have the right to stop providing information at any time you wish or skip any question you consider inappropriate. Your refusal to participate in the study or your decision to withdraw from that at any time will not affect your treatment.

**WHOM TO CONTACT:**

You should ask the person in charge any questions you may have about this research. You should ask him questions in the future if you do not understand something that is being done. The researchers will tell you anything new they learn that they think will affect you.

If you want to talk to anyone about this research you should call the person in charge of the study, [**Michael Thompson**] at [**phone number: (374 1) 51 25 92 /e-mail: mthompo@aua.am**].

If you want to talk to anyone about the research study because you feel you have not been treated fairly or think you have been hurt by joining the study you should contact the American University of Armenia at (374 1) 51 25 12

-----